DURECT (DRRX) Competitors $1.91 0.00 (0.00%) As of 02:21 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock DRRX vs. ALEC, PRQR, IMMP, ENGN, SOPH, OGI, TKNO, EDIT, AVTE, and ANNXShould you be buying DURECT stock or one of its competitors? The main competitors of DURECT include Alector (ALEC), ProQR Therapeutics (PRQR), Prima BioMed (IMMP), enGene (ENGN), SOPHiA GENETICS (SOPH), Organigram Global (OGI), Alpha Teknova (TKNO), Editas Medicine (EDIT), Aerovate Therapeutics (AVTE), and Annexon (ANNX). These companies are all part of the "pharmaceutical products" industry. DURECT vs. Its Competitors Alector ProQR Therapeutics Prima BioMed enGene SOPHiA GENETICS Organigram Global Alpha Teknova Editas Medicine Aerovate Therapeutics Annexon Alector (NASDAQ:ALEC) and DURECT (NASDAQ:DRRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings. Which has more risk & volatility, ALEC or DRRX? Alector has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500. Comparatively, DURECT has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Is ALEC or DRRX more profitable? DURECT has a net margin of -96.19% compared to Alector's net margin of -142.10%. Alector's return on equity of -112.06% beat DURECT's return on equity.Company Net Margins Return on Equity Return on Assets Alector-142.10% -112.06% -26.37% DURECT -96.19%-259.16%-71.78% Which has preferable valuation and earnings, ALEC or DRRX? DURECT has lower revenue, but higher earnings than Alector. DURECT is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlector$100.56M3.05-$119.05M-$1.16-2.62DURECT$2.03M29.21-$8.32M-$0.10-19.10 Does the media prefer ALEC or DRRX? In the previous week, Alector had 6 more articles in the media than DURECT. MarketBeat recorded 6 mentions for Alector and 0 mentions for DURECT. Alector's average media sentiment score of 0.89 beat DURECT's score of 0.75 indicating that Alector is being referred to more favorably in the media. Company Overall Sentiment Alector Positive DURECT Positive Do insiders and institutionals believe in ALEC or DRRX? 85.8% of Alector shares are held by institutional investors. Comparatively, 28.0% of DURECT shares are held by institutional investors. 9.7% of Alector shares are held by company insiders. Comparatively, 3.2% of DURECT shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Do analysts prefer ALEC or DRRX? Alector presently has a consensus target price of $4.17, indicating a potential upside of 37.29%. Given Alector's stronger consensus rating and higher possible upside, research analysts clearly believe Alector is more favorable than DURECT.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alector 2 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.29DURECT 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryAlector beats DURECT on 12 of the 16 factors compared between the two stocks. Get DURECT News Delivered to You Automatically Sign up to receive the latest news and ratings for DRRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DRRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRRX vs. The Competition Export to ExcelMetricDURECTMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$59.31M$2.63B$5.77B$9.91BDividend YieldN/A49.35%6.67%4.51%P/E Ratio-19.1023.2975.8026.59Price / Sales29.21733.92555.58120.92Price / CashN/A169.7737.1158.92Price / Book6.595.4311.446.06Net Income-$8.32M$32.95M$3.29B$266.42M7 Day Performance-0.52%1.71%0.41%-0.17%1 Month Performance3.24%6.72%6.69%3.69%1 Year Performance17.90%0.13%59.20%23.46% DURECT Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRRXDURECT0.9762 of 5 stars$1.91flatN/A+20.1%$59.31M$2.03M-19.1080Positive NewsALECAlector4.0254 of 5 stars$2.35-1.7%$4.17+77.3%-39.0%$237.85M$100.56M-2.03270News CoveragePRQRProQR Therapeutics2.327 of 5 stars$2.25+2.7%$8.00+255.6%+26.1%$236.73M$20.46M-4.89180IMMPPrima BioMed1.0053 of 5 stars$1.61-3.0%$7.00+334.8%-36.0%$236.33M$5.14M0.002,021Positive NewsENGNenGene3.1712 of 5 stars$4.62-2.7%$23.29+404.0%-24.4%$236.11MN/A-2.8031Upcoming EarningsShort Interest ↓SOPHSOPHiA GENETICS2.1741 of 5 stars$3.46+4.5%$8.00+131.2%-9.3%$233.82M$65.17M-7.86520News CoverageShort Interest ↑OGIOrganigram Global1.2644 of 5 stars$1.73flatN/A-10.6%$231.91M$117.47M34.61860TKNOAlpha Teknova2.9871 of 5 stars$4.32+0.2%$10.00+131.5%-4.5%$231.19M$37.74M-10.29240Positive NewsEDITEditas Medicine4.0607 of 5 stars$2.57-3.0%$5.10+98.4%-28.0%$231.10M$32.31M-0.90230Trending NewsAnalyst ForecastAnalyst RevisionAVTEAerovate TherapeuticsN/A$7.90-2.2%N/A-88.7%$228.98MN/A-2.6420News CoveragePositive NewsHigh Trading VolumeANNXAnnexon2.4476 of 5 stars$2.06-2.8%$12.50+506.8%-61.5%$226.37MN/A-1.6060News CoveragePositive News Related Companies and Tools Related Companies ALEC Competitors PRQR Competitors IMMP Competitors ENGN Competitors SOPH Competitors OGI Competitors TKNO Competitors EDIT Competitors AVTE Competitors ANNX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DRRX) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DURECT Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share DURECT With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DRRX Stock Alerts